Stockreport

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate [Seeking Alpha]

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence. Regeneron benefits financially from Dupixe [Read more]